Xinhua News Agency, Beijing, February 8th: Zhou Zhou, a reporter from Xinhua News Agency in Washington, and Zhang Jiawei, a reporter in London: The U.S. and U.K. institutions announced on the 7th that the development of a new coronavirus vaccine for each side is progressing smoothly and is expected to enter the clinic soon.
Infectious Diseases under the National Institutes of Health
Anthony Fauchi, director of the National Institute of Allergy and Infectious Diseases under the National Institutes of Health, said on the 7th that the new Coronavirus vaccine jointly developed by the National Institutes of Health and the biotechnology company Modena is expected to enter a phase in two and a half months Clinical trial phase.
At a conference held by the U.S. Department of Health, Fauci said that researchers obtained data from viral gene sequences published by their Chinese counterparts and successfully injected the genes into Modena’s messenger ribonucleic acid (mRNA) platform to begin directing proteins. Synthetic, which marks the first step in vaccine development has been successful. Next, researchers will inject these proteins into mice to induce immunogenicity. If all goes well, a Phase I clinical trial will be available within two and a half months.
The University of Oxford announcement
The University of Oxford announced on the 7th that the Jenner Institute team under the university is preparing for clinical trials of a vaccine candidate against the new coronavirus.
According to the school, the “seed stocks” of the candidate vaccines are being produced in a clinical biomanufacturing facility at the University of Oxford. They will then be transferred to an Italian manufacturer with plans to produce 1,000 doses of the vaccine for clinical trials.
Previously, the Middle East Respiratory Syndrome (MERS) vaccine developed by Jenner Institute has shown good results in the first phase of clinical trials, and a single dose can trigger a strong immune response against the MERS virus in the human body. The researchers said that they are using the same technical approach as the MERS vaccine to develop a vaccine against the new Coronavirus virus, which can reduce the clinical trial preparation time for the new vaccine.